2013 Biosimilars Pharmaceutical Companies 
Express Pharma
MARCH 16, 2025
In India, pharmaceutical companies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs.
European Pharmaceutical Review
NOVEMBER 8, 2022
2) limiting the scope and number of patents asserted in litigation against proposed biosimilar entrants. 4) prohibiting ‘product hopping’ and interference with generic and biosimilar substitutions. 5) monitoring access to biosimilars. 3) policing anticompetitive settlements between competing drug manufacturers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 14, 2021
Not so China, and especially not so the lead five European countries – on average European pharmaceutical companies saw a loss of 30% of the interactive time they previously had with healthcare professionals in 2020. Biosimilars accelerate. Focus on customer engagement impact. Pharma pivots East.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 23 April 2013.
PharmaShots
MARCH 29, 2023
Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Currently, the drug is not accessible in generic form.
Expert insights. Personalized for you.
110 
Let's personalize your content